Consistent improvement with eculizumab across muscle groups in myasthenia gravis

To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups.

[1]  M. Benatar,et al.  Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis , 2019, Muscle & nerve.

[2]  J. Vissing,et al.  Correlation between myasthenia gravis−activities of daily living (MG‐ADL) and quantitative myasthenia gravis (QMG) assessments of anti−acetylcholine receptor antibody−positive refractory generalized myasthenia gravis in the phase 3 regain study , 2018, Muscle & nerve.

[3]  N. Engel-Nitz,et al.  Burden of illness in patients with treatment refractory myasthenia gravis , 2018, Muscle & nerve.

[4]  G. L. Masson,et al.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.

[5]  J. Kissel,et al.  QMG and MG‐ADL correlations: Study of eculizumab treatment of myasthenia gravis , 2017, Muscle & nerve.

[6]  A. Davis,et al.  Myasthenia Gravis Impairment Index , 2017, Neurology.

[7]  J. Guptill,et al.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis , 2015, Neurotherapeutics.

[8]  K. Buzzard,et al.  Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis , 2015, Muscle & nerve.

[9]  G. Wolfe,et al.  Treatment-Refractory Myasthenia Gravis , 2014, Journal of clinical neuromuscular disease.

[10]  J. Goldstein,et al.  Clinical Characteristics of Refractory Myasthenia Gravis Patients , 2013, The Yale journal of biology and medicine.

[11]  J. Goldstein,et al.  Response of patients with refractory myasthenia gravis to rituximab: a retrospective study , 2011, Therapeutic advances in neurological disorders.

[12]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value , 2011, Neurology.

[13]  Richard J. Jones,et al.  Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.

[14]  M. Pagala,et al.  Lifetime course of myasthenia gravis , 2008, Muscle & nerve.

[15]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[16]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[17]  D. Pareyson,et al.  Anti AChR antibody: Relevance to diagnosis and clinical aspects of myasthenia gravis , 1988, The Italian Journal of Neurological Sciences.

[18]  A. Vincent,et al.  Antibodies in Myasthenia Gravis and Related Disorders , 2003, Annals of the New York Academy of Sciences.

[19]  G. Wolfe,et al.  Myasthenia gravis activities of daily living profile , 1999, Neurology.

[20]  D. Compston,et al.  Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England , 1998, Journal of neurology, neurosurgery, and psychiatry.

[21]  R. Barohn,et al.  Reliability Testing of the Quantitative Myasthenia Gravis Score a , 1998, Annals of the New York Academy of Sciences.

[22]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.

[23]  F. Somnier,et al.  Clinical implementation of anti-acetylcholine receptor antibodies. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[24]  R. Bradley,et al.  Diagnostic sensitivity of the laboratory tests in myasthenia gravis , 1992, Muscle & nerve.

[25]  G. Biesecker,et al.  Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. , 1989, Journal of immunology.

[26]  A. Vincent,et al.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[27]  Michael J. Campbell,et al.  Statistics at Square One , 1976, British medical journal.